Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...